Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chong, Chen, Xin, Zang, Dan, Lan, Xiaoying, Liao, Siyan, Yang, Changshan, Zhang, Peiquan, Wu, Jinjie, Li, Xiaofen, Liu, Ningning, Liao, Yuning, Huang, Hongbiao, Shi, Xianping, Jiang, Lili, Liu, Xiuhua, He, Zhimin, Wang, Xuejun, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287571/
https://www.ncbi.nlm.nih.gov/pubmed/27381943
http://dx.doi.org/10.1016/j.bcp.2016.06.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287571/
https://www.ncbi.nlm.nih.gov/pubmed/27381943
http://dx.doi.org/10.1016/j.bcp.2016.06.019

Ejemplares similares